Back to Search Start Over

Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands

Authors :
A. Baalbergen
Ruud L.M. Bekkers
Guus Fons
Brigitte F. M. Slangen
Gabe S. Sonke
K.K. Van de Vijver
M.A. van der Aa
M. Timmermans
Petra L.M. Zusterzeel
Roy F.P.M. Kruitwagen
Eva Maria Roes
Arnold-Jan Kruse
C. G. Gerestein
Obstetrie & Gynaecologie
MUMC+: MA Medische Staf Obstetrie Gynaecologie (9)
RS: GROW - R2 - Basic and Translational Cancer Biology
MUMC+: MA Obstetrie Gynaecologie (3)
MUMC+: MA Arts Assistenten Obstetrie Gynaecologie (9)
MUMC+: MA Niet Med Staf Onderz Beh Obstetrie Gyn (9)
MUMC+: MA Toegelatenen Obstetrie Gynaecologie (9)
Obstetrics and Gynaecology
CCA - Cancer Treatment and Quality of Life
Obstetrics & Gynecology
Source :
European Journal of Surgical Oncology, 45, 8, pp. 1425-1431, European Journal of Surgical Oncology, 45(8), 1425-1431. ELSEVIER SCI LTD, European journal of surgical oncology. W.B. Saunders Ltd, European Journal of Surgical Oncology, 45, 1425-1431, European Journal of Surgical Oncology, 45(8), 1425-1431. W.B. Saunders
Publication Year :
2019

Abstract

Introduction: The care for patients with epithelial ovarian cancer(EOC) is organised in eight different geographical regions in the Netherlands. This situation allows us to study differences in practice patterns and outcomes between geographical regions for patients with FIGO stage IIIC and IV.Methods: We identified all EOC patients who were diagnosed with FIGO stage IIIC or IV between 01.01.2008 and 31.12.2015 from the Netherlands Cancer Registry. Descriptive statistics were used to summarize treatment and treatment sequence(primary cytoreductive surgery(PCS) or neoadjuvant chemotherapy and interval cytoreductive surgery(NACT-ICS)). Moreover, outcome of surgery was compared between geographical regions. Multilevel logistic regression was used to assess whether existing variation is explained by geographical region and case-mix factors.Results: Overall, 6,741 patients were diagnosed with FIGO IIIC or IV disease. There were no differences in the percentage of patients that received any form of treatment between the geographical regions(range 80-86%, P=0.162). In patients that received cytoreductive surgery and chemotherapy, a significant variation between the geographical regions was observed in the use of PCS and NACT-ICS(PCS: 24-48%, P Conclusion: We observed a significant variation in treatment approach for advanced EOC between geographical regions in the Netherlands. Furthermore, the probability to achieve no residual disease differed significantly between regions, regardless of treatment sequence. This may suggest that surgical outcomes can be improved across geographical regions. (C) 2019 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Details

ISSN :
07487983
Database :
OpenAIRE
Journal :
European Journal of Surgical Oncology, 45, 8, pp. 1425-1431, European Journal of Surgical Oncology, 45(8), 1425-1431. ELSEVIER SCI LTD, European journal of surgical oncology. W.B. Saunders Ltd, European Journal of Surgical Oncology, 45, 1425-1431, European Journal of Surgical Oncology, 45(8), 1425-1431. W.B. Saunders
Accession number :
edsair.doi.dedup.....f8b899db7fd2d3b79b336da56a0c22ed